<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220879</url>
  </required_header>
  <id_info>
    <org_study_id>2019KYPJ148</org_study_id>
    <nct_id>NCT04220879</nct_id>
  </id_info>
  <brief_title>Study on Intraocular Structural Parameters and Surgical Effect Before and After the Onset of Malignant Glaucoma</brief_title>
  <acronym>MG</acronym>
  <official_title>Study on Intraocular Structural Parameters and Surgical Effect Before and After the Onset of Malignant Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this retrospective observational study, we collected intraocular structure parameters of
      malignant glaucoma and primary angle closure glaucoma. Anterior chamber depth (ACD) and width
      (ACW), lens vault (LV), ciliary process-ciliary process distance(CCD), trabecular-ciliary
      processes distance (TCPD), ciliary body max thickness (CBMT), peripheral iris thickness
      (PIT), trabecular ciliary process angle (TCPA), and anterior vault (AV), were measured by
      ultrasound biomicroscopy. Other parameters measured by A-scan ultrasonography and optical
      coherence tomography. To analyze the high risk factors and the possible pathogenesis of the
      disease and discuss the long-term effect of different treatment methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcome Measures:

      Anterior chamber depth (ACD) and width (ACW), lens vault (LV), ciliary process-ciliary
      process distance(CCD), trabecular-ciliary processes distance (TCPD), ciliary body max
      thickness (CBMT), peripheral iris thickness (PIT), trabecular ciliary process angle (TCPA),
      and anterior vault (AV), were measured by ultrasound biomicroscopy. Other parameters measured
      by A-scan ultrasonography and optical coherence tomography.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">November 24, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Trabecular ciliary process angle</measure>
    <time_frame>baseline</time_frame>
    <description>TCPA is measured with its apex at the scleral spur, one arm along the posterior corneal surface, and another arm along the most anterior surface of the ciliary body</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Choroidal vascularity parameter</measure>
    <time_frame>baseline</time_frame>
    <description>Choroidal vascularity parameter is a vessel ratio measured by optical coherence tomographic images</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Malignant Glaucoma</condition>
  <arm_group>
    <arm_group_label>Malignant Glaucoma</arm_group_label>
    <description>To determine the biometric measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fellow Eyes</arm_group_label>
    <description>To determine the biometric measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Eyes</arm_group_label>
    <description>To determine the biometric measurements.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients ï¼ž=18 years old with or without malignant glaucoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: (1) history of operation, (2) diagnosis of MG, and (3) eyes with clear
        optical media.

        Exclusion Criteria:(1)hypertension or diabetes and (2) diagnosis of ocular fundus diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chengguo O Zuo</last_name>
    <role>Study Director</role>
    <affiliation>Zhognshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dingqiao O Wang, M.D</last_name>
    <phone>020-66615461</phone>
    <phone_ext>02066615461</phone_ext>
    <email>wangdingqiao@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chengguo O Zuo, M.D,Ph.D</last_name>
    <phone>wangdingqiao@163.com</phone>
    <phone_ext>02066615461</phone_ext>
    <email>chengguozuo@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhognshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingqiao O Wang</last_name>
      <phone>02066615461</phone>
      <phone_ext>02066615461</phone_ext>
      <email>wangdingqiao@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chengguo O Zuo</last_name>
      <phone>02066615461</phone>
      <phone_ext>02066615461</phone_ext>
      <email>chengguozuo@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 5, 2020</last_update_submitted>
  <last_update_submitted_qc>January 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Glaucoma</keyword>
  <keyword>Biometric Measurements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) needed to be keep security.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

